Home / Health / Alopecia Trial Shows Promising Hair Regrowth
Alopecia Trial Shows Promising Hair Regrowth
14 Jul
Summary
- Bempikibart trial showed 35.3% mean reduction in scalp hair loss.
- 40% of participants achieved significant scalp coverage recovery.
- Drug has a well-tolerated safety profile with no serious adverse events.
Q32 Bio has announced encouraging 36-week top-line data from Part B of its Phase IIa SIGNAL-AA trial for bempikibart, a treatment for severe alopecia areata. The study indicated a mean reduction of 35.3% in the Alopecia Severity Score (SALT) among participants in the modified intent-to-treat group.
Further analysis revealed that 40% of the modified intent-to-treat group achieved a SALT-20 response, signifying at least 80% scalp hair coverage. The drug, bempikibart, which targets the IL-7Rα pathway, demonstrated a generally well-tolerated safety profile throughout the trial, with no new safety signals or treatment-related serious adverse events reported.
Q32 Bio is planning to advance bempikibart into a registration-directed program in the first half of 2027. The company expressed confidence in the drug's potential to offer a differentiated and durable alternative to existing therapies for patients with alopecia areata.
